3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead

Key Points

• Almonty Industries is restarting a South Korean tungsten mine as U.S. restrictions on Chinese tungsten begin January 1, with a design-capacity update expected within about 60 days.
• Kopin builds high-performance displays for military helmets and drones, recently won an $18 million contract and presents at CES in January.
• Cullinan Therapeutics has 2 shots on goal: autoimmune data expected around December and a partnered lung cancer drug with an FDA decision expected in late February.

Small caps led the market into spring and have been handing it back ever since. The Russell 2000 has cooled, defense and drone names sit well off their highs, and the riskier corners of biotech and critical minerals have been marked down right alongside them.

That creates a specific problem for growth investors. A stock can look cheap for a very long time and simply drift, thin volume, no news, nothing forcing anyone to change their mind.

A date breaks the drift. Three growth stocks trading under $20 each have one on the calendar within the next several months, and none is a pure AI play, which counts for something in a market crowded around the same handful of names.

A Great Story With No Date Is Just Dead Money

Kristin Orman, research director at The Oxford Club, starts with the story and ends with the calendar. A compelling narrative without a concrete date to change how investors value a company tends to go nowhere.

The Oxford Club screens thousands of U.S.-listed stocks for growing revenue and earnings, lower debt and higher beta, a measure of how sharply a stock moves relative to the market. Beta cuts both ways, so the list then narrows to strong management teams and binary events.

Orman looks past Wall Street ratings, a habit from training under short sellers early in her career. She also points to a seasonal pattern from her own research, with smaller stocks tending to outperform into year-end and December often the strongest month.

A Jan. 1 Tungsten Deadline Puts Almonty’s Ramp-Up on the Clock

Almonty Industries NASDAQ: ALM mines tungsten, an extremely hard metal used in aerospace, electronics, semiconductors, and defense. CEO Lewis Black entered the business after a school friend won a tungsten mine in Thailand in a card game, then founded Almonty in 2011.

Geography is what matters now. China supplies more than 80% of the world’s tungsten, and U.S. restrictions on Chinese supply begin Jan. 1. Almonty’s Sangdong mine in South Korea produced tungsten this September for the first time in more than three decades and entered Phase I commercial operation, with over 90% of that output already committed under a 21-year offtake agreement.

A restart also eases the biggest risk in mining, which is funding, because development costs run lower than on a new find. Orman likes that the founder holds a meaningful stake.

Shares have fallen sharply over the past month and trade in the $9 range against a 52-week high of above $24. Management used its October investor day to flag an update on reaching design capacity within roughly 60 days. The consensus price target still implies triple-digit upside, though several firms have trimmed their numbers since September, which is the honest version of that figure.

Kopin’s January Trade Show Pitch Puts It in Front of Buyers and Wall Street

Kopin Corporation NASDAQ: KOPN makes the tiny, high-performance displays built into military helmets and vehicle systems, the components that help soldiers see better in the field. It also supplies drone programs and is working on moving AI-related information more efficiently, which makes it AI-adjacent rather than a pure-play.

Orman files Kopin under consumer electronics, and the next catalyst fits the label: a January presentation at the Consumer Electronics Show (CES), where companies such as Garmin NYSE: GRMN unveil new technology. Buyers attend, and so does Wall Street.

With a market capitalization of nearly $630 million, Kopin recently won an $18.6 million U.S. Army contract for MicroLED displays. Second-quarter revenue grew 51% year over year, and Orman expects growth above 50% this year and another 30% next year, with the stock potentially doubling over 12 to 18 months as Department of Defense orders build.

The chart tells a more nuanced story than the broader drone sell-off suggests: shares are up roughly 60% year to date, even after a steep pullback from September highs. The risk is interest rates, since smaller companies need capital, and higher borrowing costs make it pricier. The upside is a defense-anchored customer base, a layer of protection many small caps lack.

Cullinan’s February 2027 FDA Date Could End Its Pre-Revenue Discount

Cullinan Therapeutics NASDAQ: CGEM is pre-revenue with two shots on goal. Its in-house autoimmune program, CLN-978, aims at durable treatment rather than therapies patients take over and over, with data expected around year-end.

The second is zipalertinib, a lung cancer drug partnered with Taiho Oncology that delivered a statistically significant progression-free survival benefit alongside chemotherapy in the Phase 3 REZILIENT3 trial. Its Prescription Drug User Fee Act (PDUFA) date, the U.S. Food and Drug Administration deadline for a ruling, is Feb. 27, 2027, one of a long list of upcoming FDA decision dates that give biotech investors something concrete to trade against.

That date is the reframe. Approval would mean investors no longer have to value Cullinan as a high-risk biotech with nothing on the market.

The balance sheet buys the time to get there, with roughly $393 million in cash reported for the first quarter and a runway into 2029. Institutional ownership runs high, and the analyst consensus sits in the low $30s with a high near $42.

The risk is that trials fail, or the FDA rejects a drug or attaches a safety warning that slows adoption. The upside is two large addressable markets and the tendency of approved drugs to expand into new indications.

What to Watch on These 3 Growth Stocks Under $20

Strip away the sectors, and these three rhyme. Almonty, Kopin, and Cullinan each pulled back hard after a strong run, each sits in the higher-beta, smaller-cap bucket that has lagged, and each has a dated event that could force a repricing.

None of it depends on AI enthusiasm or a rate-cut rally, though cheaper money would help. It depends on execution, with Almonty hitting design capacity, Kopin converting CES exposure and Army contracts into orders, and Cullinan clearing the FDA. Stumble on any of those, and the volatility that makes these names interesting cuts the other way.

That execution question is the one Orman keeps coming back to, and it is not unique to tungsten, displays, or biotech. The same filter applies to the AI infrastructure names that have run up on story alone, with no dated event behind them. The Oxford Club built a full series of special reports around exactly that gap, covering the high-beta, smaller-cap names tied to phase two of the AI boom that have not made their move yet. If you want the catalyst-first version of the AI trade, that is where the rest of the work lives.

Stay focused on the calendar, because for small caps like these, dated catalysts are what move the share price.